

Boston Scientific

Boston Scientific to Appoint Brenda Becker Senior Vice President, Global Government Affairs

PRNewswire-FirstCall
NATICK, Mass.
(NYSE:BSX)

NATICK, Mass., Nov. 15 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Brenda Becker will be appointed Senior Vice President of Global Government Affairs. She will be responsible for managing the Company's global government affairs function, as well as its corporate public policy and political action committee. Brenda plans to join the Company in January and will report to Paul LaViolette, Chief Operating Officer.

"We are extremely pleased to have someone of Brenda's talent and distinguished reputation leading our government affairs function," said LaViolette. "She brings an outstanding track record of success to Boston Scientific with more than 20 years of governmental experience working in the nation's capitol."

Brenda is currently Assistant to the Vice President for Legislative Affairs. In this role, she is responsible for advising the Vice President of the United States and senior White House staff on legislative strategy in the House and Senate. Brenda is well respected for her knowledge and depth of experience in both the Legislative and Executive branches.

Previously, Brenda was confirmed by the Senate as Assistant Secretary for Legislative and Intergovernmental Affairs for the United States Department of Commerce, where she provided advice and counsel to the Secretary of Commerce and other senior Commerce officials on Congressional and intergovernmental affairs issues. Prior to her role at the Commerce Department, Brenda was Vice President for Congressional Communications at the Blue Cross and Blue Shield Association.

Brenda holds a B.A. in Political Science and Public Administration from Michigan State University and an M.B.A. from Central Michigan University. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit <http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT:

Dan Brennan
508-650-8538 (office)
617-459-2703 (mobile)
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations

Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Dan Brennan, +1-508-650-8538, or mobile: +1-617-459-2703, or Paul Donovan, +1-508-650-8541, mobile: +1-508-667-5165, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=58916>